213 related articles for article (PubMed ID: 1285875)
1. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy.
Abramson SB; Buyon JP
Am J Reprod Immunol; 1992; 28(3-4):183-7. PubMed ID: 1285875
[TBL] [Abstract][Full Text] [Related]
2. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
[TBL] [Abstract][Full Text] [Related]
3. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
Buyon JP; Tamerius J; Belmont HM; Abramson SB
Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018
[TBL] [Abstract][Full Text] [Related]
4. Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient.
Lockshin MD; Harpel PC; Druzin ML; Becker CG; Klein RF; Watson RM; Elkon KB; Reinitz E
Arthritis Rheum; 1985 Jan; 28(1):58-66. PubMed ID: 3917671
[TBL] [Abstract][Full Text] [Related]
5. [Components of the classical complement pathway in systemic lupus erythematosus].
Maillet F; Goetz J; Hauptmann G; Clauvel JP; Mery JP; Kahn MF; Kazatchkine M
Presse Med; 1987 Mar; 16(8):378-82. PubMed ID: 2950498
[TBL] [Abstract][Full Text] [Related]
6. Alternative complement pathway in hypocomplementemic/normal C1s-C1 inhibitor complex patients with SLE.
Levy RA; Qamar T; Lockshin MD
Clin Exp Rheumatol; 1990; 8(1):11-5. PubMed ID: 2347130
[TBL] [Abstract][Full Text] [Related]
7. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia.
Buyon JP; Cronstein BN; Morris M; Tanner M; Weissmann G
Am J Med; 1986 Aug; 81(2):194-200. PubMed ID: 3740078
[TBL] [Abstract][Full Text] [Related]
8. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
[TBL] [Abstract][Full Text] [Related]
9. Activation of the complement system in normal pregnancy and preeclampsia.
Derzsy Z; Prohászka Z; Rigó J; Füst G; Molvarec A
Mol Immunol; 2010 Apr; 47(7-8):1500-6. PubMed ID: 20181396
[TBL] [Abstract][Full Text] [Related]
10. A Review of Complement Activation in SLE.
Weinstein A; Alexander RV; Zack DJ
Curr Rheumatol Rep; 2021 Feb; 23(3):16. PubMed ID: 33569681
[TBL] [Abstract][Full Text] [Related]
11. Complement activation in patients with systemic lupus erythematosus without nephritis.
Mollnes TE; Haga HJ; Brun JG; Nielsen EW; Sjöholm A; Sturfeldt G; Mårtensson U; Bergh K; Rekvig OP
Rheumatology (Oxford); 1999 Oct; 38(10):933-40. PubMed ID: 10534542
[TBL] [Abstract][Full Text] [Related]
12. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
Kim MY; Guerra MM; Kaplowitz E; Laskin CA; Petri M; Branch DW; Lockshin MD; Sammaritano LR; Merrill JT; Porter TF; Sawitzke A; Lynch AM; Buyon JP; Salmon JE
Ann Rheum Dis; 2018 Apr; 77(4):549-555. PubMed ID: 29371202
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis.
Hopkins P; Belmont HM; Buyon J; Philips M; Weissmann G; Abramson SB
Arthritis Rheum; 1988 May; 31(5):632-41. PubMed ID: 3259882
[TBL] [Abstract][Full Text] [Related]
14. Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus.
Lockshin MD; Qamar T; Redecha P; Harpel PC
Arthritis Rheum; 1986 Dec; 29(12):1467-72. PubMed ID: 3492208
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
16. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).
Lloyd W; Schur PH
Medicine (Baltimore); 1981 May; 60(3):208-17. PubMed ID: 7231154
[TBL] [Abstract][Full Text] [Related]
17. The value of complement activation products in the assessment of systemic lupus erythematosus flares.
Porcel JM; Ordi J; Castro-Salomo A; Vilardell M; Rodrigo MJ; Gene T; Warburton F; Kraus M; Vergani D
Clin Immunol Immunopathol; 1995 Mar; 74(3):283-8. PubMed ID: 7859418
[TBL] [Abstract][Full Text] [Related]
18. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
Ho A; Barr SG; Magder LS; Petri M
Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcomes of women with coexisting systemic lupus erythematosus flare and preeclampsia.
Aoki S; Mochimaru A; Yamamoto Y; Kurasawa K; Takahashi T; Hirahara F
Mod Rheumatol; 2015 May; 25(3):410-4. PubMed ID: 25924546
[TBL] [Abstract][Full Text] [Related]
20. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.
Mejia-Vilet JM; Gómez-Ruiz IA; Cruz C; Méndez-Pérez RA; Comunidad-Bonilla RA; Uribe-Uribe NO; Nuñez-Alvarez CA; Morales-Buenrostro LE
Clin Rheumatol; 2021 Jun; 40(6):2233-2242. PubMed ID: 33170371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]